One of the most common heart/thyroid assumptions - thrown at thyroid patents everywhere - is that atrial fibrillation is almost certainly related to hyperthyroidism or over-medication with thyroid hormones and is a symptom of some form of thyrotoxicosis.
Some, quite a few, stalwarts here have repeatedly pointed out that is fundamentally untrue.
Personally, I have found that too little levothyroxine sees my permanent atrial fibrillation worsen considerably. While I always have afib, the rate goes up if I am under-medicated. And, as one bit of evidence, my smart watch keeps telling me it is too high. (Of course, I can choose the level at which it warns.)
Now, at long last, we have a paper with a conclusion:
This study found that subclinical hypothyroidism was more prevalent (4.9%) than thyrotoxicosis (1.2%) among patients presenting with acute NOAF.
They then admit hypothyroidism plays a more significant role than thyrotoxicosis.
I get the feeling that this has been a bit of a surprise to them. But not to quite a few of us!
Prevalence of abnormal thyroid hormone levels in acute new-onset atrial fibrillation
Abstract
Introduction: Known risk factors for new-onset atrial fibrillation/flutter (NOAF) include thyrotoxicosis and subclinical hypothyroidism. While prior research has predominantly explored the link between thyrotoxicosis and NOAF, the presence of subclinical hypothyroidism among patients presenting with acute NOAF in the emergency department (ED) remains an underexplored area of inquiry. This study aimed to assess the prevalence of undiagnosed thyrotoxicosis and subclinical hypothyroidism in patients with acute NOAF diagnosed in the ED.
Methods: This registry-based cohort study was conducted in the ED at Vrinnevi Hospital in Sweden during the years 2018, 2020, and 2022, with a 1-year follow-up period. Patients ≥18 years diagnosed with NOAF in the ED, with no ongoing thyroid hormone substitution or previous documented thyroid abnormality within the past 2 years, were included. The primary outcome was the diagnosis of thyrotoxicosis or subclinical hypothyroidism either in the ED or during a 1-year follow-up period.
Results: 486 patients with NOAF were included in the study (43.6% females). 329 (67.7%) underwent thyroid function testing in the ED or by the end of the 1-year follow-up. In total, 16 (4.9%) patients presented with subclinical hypothyroidism while 4 (1.2%) patients presented with clinical or subclinical thyrotoxicosis.
Discussion: This study found that subclinical hypothyroidism was more prevalent (4.9%) than thyrotoxicosis (1.2%) among patients presenting with acute NOAF. These findings contrast with previous research that has predominantly linked thyrotoxicosis with acute NOAF, suggesting the need for further studies including both subclinical hypothyroidism and thyrotoxicosis in patients with NOAF.
Keywords: acute new-onset atrial fibrillation; atrial fibrillation; emergency department; hyperthyroidism; subclinical hypothyroidism; thyroid testing; thyrotoxicosis.
.
.
Conclusion
In conclusion, subclinical hypothyroidism was more frequently prevalent than thyrotoxicosis (4.9% vs. 1.2%) in patients diagnosed with acute NOAF, suggesting it may play a more significant role than previously recognized. These findings suggest that there is a need for further studies including both thyrotoxicosis as well as subclinical hypothyroidism in acute NOAF and further research into the clinical implications of subclinical hypothyroidism in this population.
Open access: